Life sciences startup Biodimension has secured ₹8 crore in fresh funding in a round led by IAN Angel Fund, as the company accelerates efforts to transform drug discovery and biomedical research through advanced biofabricated human tissue models.
The funding round also saw participation from existing investor Campus Angels Network, along with Dr. Sampath Srisailam and angel investor Aaryan Baid.
The investment will support product innovation, laboratory expansion, talent acquisition, and commercial growth as Biodimension seeks to scale its presence in India and international markets.
Funding to Strengthen Product Development and Research Infrastructure
Biodimension plans to use the newly raised capital to enhance its scientific capabilities and expand its research infrastructure.
Key focus areas for the funding include:
- Accelerating product development
- Expanding laboratory facilities
- Strengthening scientific and commercial teams
- Scaling product commercialization
- Expanding international market reach
The company aims to increase adoption of its human-relevant testing technologies among pharmaceutical, biotechnology, and cosmetic companies seeking more accurate alternatives to traditional animal-based testing methods.
Transforming Drug Discovery with Biofabricated Human Tissue Models
Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension develops advanced biofabricated human tissue and organoid models designed to improve research accuracy and predictive outcomes in life sciences.
These technologies are intended to provide researchers with human-relevant biological systems that better replicate real-world physiological responses compared to conventional animal testing methods.
As regulatory agencies and industry stakeholders increasingly advocate for alternatives to animal testing, demand for advanced tissue engineering and organoid-based research platforms continues to grow globally.
Portfolio Supports Pharmaceutical and Biotechnology Research
Biodimension offers a portfolio of specialized products and services designed to support drug discovery, toxicity testing, disease modeling, and safety assessment.
Its offerings include:
BioDEpi
Human tissue-based solutions for dermatological and skin-related research applications.
BioDFT
Advanced testing platforms designed to support pharmaceutical and biotechnology studies.
BioDPigma
Innovative human tissue models developed to improve biological research and product evaluation.
Pan-Cancer Tumour Microenvironment (TME) Biobank
A specialized research platform that provides access to cancer-related tissue models to support oncology research and precision medicine initiatives.
Bioassay-as-a-Service (BaaS)
A service-based platform that enables organizations to access advanced testing capabilities without investing in in-house laboratory infrastructure.
Together, these solutions help researchers generate more accurate insights while reducing reliance on animal-based experiments.
Growing Collaborations Across India and Singapore
Biodimension has already established partnerships with a range of organizations across the healthcare and life sciences ecosystem.
Its collaborators include:
- Pharmaceutical companies
- Biotechnology firms
- Research institutions
- Contract Research Organizations (CROs)
The company currently works with organizations in both India and Singapore, reflecting growing interest in next-generation testing technologies across the Asia-Pacific region.
Expansion Plans Focus on Oncology and International Growth
Looking ahead, Biodimension plans to strengthen its position in oncology research, one of the fastest-growing segments within the global life sciences industry.
The company intends to:
- Expand its oncology-focused research offerings
- Scale its Bioassay-as-a-Service platform
- Enhance tissue engineering capabilities
- Grow commercial partnerships
- Enter additional international markets
Southeast Asia has been identified as a key growth region as the company seeks to expand its customer base and support life sciences innovation across emerging healthcare markets.
Rising Demand for Animal Testing Alternatives
The global life sciences industry is increasingly shifting toward human-relevant research models that can deliver better predictive accuracy while addressing ethical concerns associated with animal testing.
Advancements in organoid technology, tissue engineering, and biofabrication are creating new opportunities for pharmaceutical companies to accelerate drug development and improve research outcomes.
Industry experts believe these technologies could significantly reduce drug development risks by providing more reliable insights into human biological responses during the early stages of research.
Outlook
With fresh funding, expanding scientific capabilities, and growing industry partnerships, Biodimension is positioning itself as an emerging player in the rapidly evolving field of biofabrication and human tissue engineering.
As demand for advanced research models continues to rise across pharmaceutical, biotechnology, and healthcare sectors, the company aims to play a key role in enabling more accurate, ethical, and efficient drug discovery and testing processes.
The latest investment marks an important milestone in Biodimension’s mission to advance next-generation life sciences research while reducing the industry’s dependence on animal testing.
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape. She has written extensively on fintech, AI and emerging startups.